Preliminary Results for the year to 31 January 2009

21 April 2009

LiDCO (AIM:LID), the cardiovascular monitoring company, today announces its Preliminary Results for the year ended 31 January 2009

Financial Highlights

• Revenue up 12% at £4.53m (2007/8: £4.05m)
• Product margins maintained at 81% (2007/8: 81%)
• Loss from operations reduced by 11% to £1.80m (2007/8: £2.01m)
• Loss per share reduced to 1.16p (2007/8: 1.50p)
• Cash balance £0.49m (2007/8: £2.23m)
• Loan facility replaced with combined overdraft and invoice financing facility with a maximum availability of £1.25m

Operational Highlights

• Highest single year increase in installed monitor base. LiDCOplus & rapid monitors installed base up 28% to 1,510
• Successful launch of the LiDCOrapid; 279 monitors sold or placed in first ten months
• Follow-on grant of Japanese sales and marketing license and expansion of co-marketing agreement signed with Becton Dickinson
• New distributors added for 18 territories. LiDCO products are now available in 47 countries worldwide
• Continued progress towards profitability and significant increase in level of recurring revenue
• 326 monitors sold or placed in the period up 116% - (2007/8: 151)
• Monitor revenue steady at £1.96m (2007/8: £1.93m)
• Disposables income growth in all territories up 26% from £1.99m to £2.50m
• Selected as technology for two US multi-centre patient outcome studies

Commenting on the results Terry O'Brien, Chief Executive, said: “This has been a key year for the Group and I am delighted to report that we have achieved what we set out to do at the start of the period. The successful launch of the LiDCOrapid has given us access to the potential US$800 million high-risk surgery market and has significantly enhanced our ability to grow our distribution partners and improve our routes to market. We have doubled the rate of placing monitors and have seen significant increases in recurring revenue in all territories. The foundations are now in place to increase revenues and earnings in the coming years. We have made solid, sustainable progress and are confident that in the coming year we will take our proportionate share of the growing minimally invasive hemodynamic monitoring market.”

The investor presentation "LiDCO’s Preliminary Results - twelve months ended 31 January 2009" will be available from today on the LiDCO website (www.lidco.com).

For more information please contact:

Media enquiries

About LiDCO Group Plc

LiDCO is a supplier of minimally invasive hemodynamic monitoring equipment and disposables to hospitals. These products are used primarily for the management of hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology significantly reduces the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.

The Company's manufacturing facility is in Hoxton, London, and its current products are:

* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)

* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care. The monitor features many clinical benefits. These enable acute-care physicians to get accurate and immediate feedback on the patient’s fluid and hemodynamic status - a key measure of overall well-being during and after surgery.  These benefits are:

• Early and rapid warning of change
• Clear indication of therapeutic route: fluid or drug
• Quantification of hemodynamic response, particularly stroke volume
• Permits more effective delivery of fluids - the right amount at the right time
• Advanced hemodynamic care has been shown to contribute to:
  • - Reduced morbidity and complications
  • - Reduced length of stay
  • - Reduced overall cost of care

* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid Monitors.

* LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase

LiDCO Distribution Network:

The Company sells direct to hospitals in the UK, and elsewhere predominantly through a worldwide network of speciality critical care and anesthesia distributors.